Alternative Approaches in Gene Discovery and Characterization in Alzheimer’s Disease

[1]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[2]  R. Wilson,et al.  Relation of neuropathology to cognition in persons without cognitive impairment , 2012, Annals of neurology.

[3]  M. Rattray,et al.  Gene expression profiling in human neurodegenerative disease , 2012, Nature Reviews Neurology.

[4]  Margaret A. Pericak-Vance,et al.  Novel late-onset Alzheimer disease loci variants associate with brain gene expression , 2012, Neurology.

[5]  Margaret A. Pericak-Vance,et al.  Brain Expression Genome-Wide Association Study (eGWAS) Identifies Human Disease-Associated Variants , 2012, PLoS genetics.

[6]  A. J. Butte,et al.  Integration of disease-specific single nucleotide polymorphisms, expression quantitative trait loci and coexpression networks reveal novel candidate genes for type 2 diabetes , 2012, Diabetologia.

[7]  Jason J. Corneveaux,et al.  A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. , 2012, Human molecular genetics.

[8]  S. Leurgans,et al.  Cognitive reserve, presynaptic proteins and dementia in the elderly , 2012, Translational Psychiatry.

[9]  Jason J. Corneveaux,et al.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.

[10]  Asha A. Nair,et al.  Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications , 2012, Molecular Neurodegeneration.

[11]  D. Bennett,et al.  Alzheimer disease susceptibility loci: evidence for a protein network under natural selection. , 2012, American journal of human genetics.

[12]  S. Leurgans,et al.  The CETP I405V polymorphism is associated with an increased risk of Alzheimer’s disease , 2012, Aging cell.

[13]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[14]  N. Zilka,et al.  Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways , 2012, Journal of Neuroinflammation.

[15]  J M Starr,et al.  APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921 , 2012, Molecular Psychiatry.

[16]  M C O'Donovan,et al.  Schizophrenia susceptibility alleles are enriched for alleles that affect gene expression in adult human brain , 2012, Molecular Psychiatry.

[17]  L. Cortellini,et al.  Genetic variation at CR1 increases risk of cerebral amyloid angiopathy , 2012, Neurology.

[18]  Jurg Ott,et al.  Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study , 2011, Neurobiology of Aging.

[19]  L. Grinberg,et al.  African ancestry protects against Alzheimer's disease-related neuropathology , 2011, Molecular Psychiatry.

[20]  H. Soares,et al.  Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment , 2011, Translational Psychiatry.

[21]  C. Jack,et al.  Chronic divalproex sodium use and brain atrophy in Alzheimer disease , 2011, Neurology.

[22]  C. Jack,et al.  Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. , 2011, Archives of general psychiatry.

[23]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Cancer.

[24]  N. Ertekin-Taner.  Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease , 2011, Molecular Neurodegeneration.

[25]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Neuroscience.

[27]  N. Pedersen,et al.  Both odor identification and ApoE-ε4 contribute to normative cognitive aging. , 2011, Psychology and aging.

[28]  P. Visser,et al.  Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  D. G. Clark,et al.  Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.

[30]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[31]  S. Leurgans,et al.  Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. , 2011, Archives of neurology.

[32]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[33]  F. Panza,et al.  Polymorphisms in glutathione S-transferase omega-1 gene and increased risk of sporadic Alzheimer disease. , 2010, Rejuvenation research.

[34]  C. Kruse,et al.  Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. , 2010, Brain : a journal of neurology.

[35]  Christopher Kircher.  COGNITIVE DECLINE IN INCIDENT ALZHEIMER DISEASE IN A COMMUNITY POPULATION , 2010, Neurology.

[36]  Vahram Haroutunian,et al.  Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia , 2010, Alzheimer's & Dementia.

[37]  T. Suuronen,et al.  Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease , 2010, Neuroscience Letters.

[38]  A. Eckert,et al.  Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer’s Disease—Therapeutic Aspects , 2010, Molecular Neurobiology.

[39]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[40]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[41]  N. Cox,et al.  Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS , 2010, PLoS genetics.

[42]  N. Ertekin-Taner.  Genetics of Alzheimer disease in the pre- and post-GWAS era , 2010, Alzheimer's Research & Therapy.

[43]  Philippe Amouyel,et al.  The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. , 2010, Trends in genetics : TIG.

[44]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[45]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[46]  Xiuzhen Zhang,et al.  Valproic acid as a promising agent to combat Alzheimer's disease , 2010, Brain Research Bulletin.

[47]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[48]  D. Bennett,et al.  The APOE ε4 Allele Is Associated with Incident Mild Cognitive Impairment among Community-Dwelling Older Persons , 2009, Neuroepidemiology.

[49]  S. DeKosky,et al.  Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease , 2009, Molecular Psychiatry.

[50]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[51]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[52]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[53]  Yaakov Stern,et al.  Cognitive Reserve: Implications for Assessment and Intervention , 2013, Folia Phoniatrica et Logopaedica.

[54]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[55]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[56]  D. Knopman,et al.  Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study , 2009, Alzheimer's & Dementia.

[57]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[58]  David A. Bennett,et al.  Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles , 2009, Neurology.

[59]  D. Stephan,et al.  Genetic control of human brain transcript expression in Alzheimer disease. , 2009, American journal of human genetics.

[60]  W. Markesbery,et al.  The Effect of APOE-ϵ4 on Dementia is Mediated by Alzheimer Neuropathology , 2009 .

[61]  R. Mayeux,et al.  Memory performance is related to amyloid and tau pathology in the hippocampus , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[62]  L. Liang,et al.  Mapping complex disease traits with global gene expression , 2009, Nature Reviews Genetics.

[63]  A. Fagan,et al.  Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta , 2009, neurogenetics.

[64]  R. Wade-Martins,et al.  Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus , 2008, Neurobiology of Aging.

[65]  W. Markesbery,et al.  AD brain pathology: Vascular origins? Results from the HAAS autopsy study , 2008, Neurobiology of Aging.

[66]  A. Fagan,et al.  Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition , 2008, Proceedings of the National Academy of Sciences.

[67]  J. Brandt,et al.  APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease , 2008, Neurology.

[68]  D. Bennett,et al.  Processing resources reduce the effect of Alzheimer pathology on other cognitive systems , 2008, Neurology.

[69]  Stian Lydersen,et al.  APOE ε4 lowers age at onset and is a high risk factor for Alzheimer's disease; A case control study from central Norway , 2008, BMC neurology.

[70]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[71]  V. Pankratz,et al.  The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.

[72]  C. Lyketsos,et al.  Apolipoprotein E genotype and lifetime cognitive decline , 2008, International Psychogeriatrics.

[73]  M. Albert,et al.  Exploring candidate gene associations with neuropsychological performance , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[74]  S. Haneuse,et al.  Pathological correlates of dementia in a longitudinal, population‐based sample of aging , 2007, Annals of neurology.

[75]  Nilüfer Ertekin-Taner,et al.  Genetics of Alzheimer's disease: a centennial review. , 2007, Neurologic clinics.

[76]  P. Thompson,et al.  Neuroimaging endophenotypes: Strategies for finding genes influencing brain structure and function , 2007, Human brain mapping.

[77]  H. Nicolini,et al.  Adjudicating neurocognitive endophenotypes for schizophrenia , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[78]  A. Myers,et al.  The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts , 2007, Neurobiology of Disease.

[79]  B. Ritz,et al.  Glutathione S-transferase mu, omega, pi, and theta class variants and smoking in Parkinson's disease , 2007, Neuroscience Letters.

[80]  M. Esiri,et al.  Haplotype-specific expression of exon 10 at the human MAPT locus. , 2006, Human molecular genetics.

[81]  H. Fung,et al.  Untangling the tau gene association with neurodegenerative disorders. , 2006, Human molecular genetics.

[82]  David A. Bennett,et al.  Decision Rules Guiding the Clinical Diagnosis of Alzheimer’s Disease in Two Community-Based Cohort Studies Compared to Standard Practice in a Clinic-Based Cohort Study , 2006, Neuroepidemiology.

[83]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[84]  N. Freimer,et al.  Endophenotypes for psychiatric disorders: ready for primetime? , 2006, Trends in genetics : TIG.

[85]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[86]  I. Gottesman,et al.  Psychiatric endophenotypes and the development of valid animal models , 2006, Genes, brain, and behavior.

[87]  C. D. de Jager,et al.  APOE alleles predict the rate of cognitive decline in Alzheimer disease , 2005, Neurology.

[88]  David A. Bennett,et al.  The Rush Memory and Aging Project: Study Design and Baseline Characteristics of the Study Cohort , 2005, Neuroepidemiology.

[89]  S. DeKosky,et al.  Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease , 2005, Neurobiology of Aging.

[90]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[91]  J. Morris,et al.  Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. , 2005, Archives of neurology.

[92]  Masatoshi Takeda,et al.  Identification of hippocampus‐related candidate genes for Alzheimer's disease , 2005, Annals of neurology.

[93]  Eileen Crimmins,et al.  Education and APOE-e4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. , 2005, The journals of gerontology. Series B, Psychological sciences and social sciences.

[94]  L. Feuk,et al.  Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. , 2005, Human molecular genetics.

[95]  E. Boerwinkle,et al.  APOE genotype and cognitive decline in a middle-aged cohort , 2005, Neurology.

[96]  F. Jessen,et al.  Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke , 2004, Neurology.

[97]  R. Kaji,et al.  Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer’s disease , 2004, Neuroscience Letters.

[98]  B. Winblad,et al.  APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging , 2004, Neurology.

[99]  Peter P. Zandi,et al.  Apolipoprotein E ϵ4 Count Affects Age at Onset of Alzheimer Disease,but Not Lifetime Susceptibility: The Cache County Study , 2004 .

[100]  R. Petersen,et al.  Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Aβ42 levels and risk for Alzheimer disease , 2004, Human mutation.

[101]  Eden R Martin,et al.  Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. , 2003, Human molecular genetics.

[102]  S. Younkin,et al.  Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. , 2003, Human molecular genetics.

[103]  J. M. Guralnik,et al.  The role of APOE-&egr;4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging , 2003 .

[104]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[105]  Simon M Laws,et al.  Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription , 2003, Journal of neurochemistry.

[106]  Yaakov Stern,et al.  Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E , 2001, Neurobiology of Aging.

[107]  D. Schaid,et al.  Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees , 2001 .

[108]  J. Blangero,et al.  Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. , 2000, Science.

[109]  A. Goate,et al.  Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease , 2000, Neurology.

[110]  Roberta F. White,et al.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. , 2000, Archives of neurology.

[111]  L. Thal,et al.  Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. , 1999, Psychology and aging.

[112]  A. Hofman,et al.  Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study , 1999, Journal of Neurology.

[113]  A. Grover,et al.  5′ Splice Site Mutations in tau Associated with the Inherited Dementia FTDP-17 Affect a Stem-Loop Structure That Regulates Alternative Splicing of Exon 10* , 1999, The Journal of Biological Chemistry.

[114]  J. Lindeboom,et al.  Association between apolipoprotein E ε4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia , 1998 .

[115]  B. Everitt,et al.  Analysis of longitudinal data , 1998, British Journal of Psychiatry.

[116]  J. Cauley,et al.  Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. , 1997, Archives of neurology.

[117]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[118]  R. Brookmeyer,et al.  Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. , 1996, Archives of neurology.

[119]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[120]  D. Schaid,et al.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. , 1995, JAMA.

[121]  A. Roses.  Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.

[122]  L A Hansen,et al.  Clinical-neuropathological correlations in Alzheimer's disease and related dementias. , 1994, Archives of neurology.

[123]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[124]  W. Kukull,et al.  The validity of 3 clinical diagnostic criteria for Alzheimer's disease , 1990, Neurology.

[125]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[126]  J. Shields,et al.  Genetic Theorizing and Schizophrenia , 1973, British Journal of Psychiatry.

[127]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[128]  W. Markesbery,et al.  The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. , 2009, Alzheimer disease and associated disorders.

[129]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[130]  P. Muchowski,et al.  Modulation of neurodegeneration by molecular chaperones , 2005, Nature Reviews Neuroscience.

[131]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[132]  M. Albert,et al.  The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. , 2003, Neurology.

[133]  J. Morris,et al.  A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia , 1998, Nature Genetics.

[134]  J. Lindeboom,et al.  Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. , 1998, Archives of neurology.

[135]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[136]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[137]  J. Simpson,et al.  Sanders-brown Center on Aging Faculty Publications Aging Genetics of Clusterin Isoform Expression and Alzheimer' S Disease Risk Repository Citation Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk , 2022 .